Imagine your body has a security system (the immune system) and some chemicals in plastics or makeup act like fake keys that trick the locks. This project finds out which combinations of these 'fake keys' cause the most trouble and lead to diseases. It uses tiny lab-grown organs and AI to map out exactly how these chemicals make us sick.
Companies struggle to predict how complex mixtures of chemicals in their products affect human health over time. Current testing often misses how these mixtures specifically target the immune system to trigger chronic diseases.
The project is building high-throughput bioassays, organoid systems, and AI-assisted knowledge graphs to map chemical-immune interactions.
If you are an ingredient manufacturer dealing with unpredictable toxicity in chemical blends — this project developed biomarkers and exposure patterns that identify health-relevant mixtures of concern. This allows you to replace risky components before they reach the market.
If you are a plastic packaging producer dealing with strict EU safety regulations — this project developed toxicity modelling and bioassays that reveal how chemicals leach and target the immune system. This helps you design materials that avoid triggering immune-mediated pathologies.
If you are a drug discovery firm dealing with complex immune-mediated diseases — this project developed organoid and co-culture systems to study how chemical mixtures trigger disease. This provides a mechanistic evidence base to identify new targets for treatment.
Based on available project data, there is no pricing information provided as this is a publicly funded EU research project.
The project focuses on high-throughput bioassays and in silico data, which are designed for large sample sizes, though industrial-scale deployment is not yet detailed.
Based on available project data, specific licensing terms are not mentioned; the project aims to provide an evidence base for policy-making and the scientific community.
The project provides evidence for policy-making and risk assessment regarding endocrine disruptors, which will likely influence future EU chemical regulations.
The project is scheduled to run from 2024-01-01 to 2027-12-31.
The consortium is purely academic and research-driven, consisting of 11 partners from 7 countries, split between 4 universities and 7 research organizations. There is a 0% industry ratio, meaning the project is currently focused on fundamental science and evidence generation rather than immediate commercial product development.
Contact HELMHOLTZ-ZENTRUM FUR UMWELTFORSCHUNG GMBH - UFZ
Contact us to track the development of these immune-toxicity biomarkers for your product pipeline.
